- NOK1.47bn
- NOK1.20bn
- NOK525.39m
- 51
- 21
- 48
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 35.52 | ||
| PEG Ratio (f) | 0.47 | ||
| EPS Growth (f) | 315.5% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.93 | ||
| Price to Tang. Book | 5.61 | ||
| Price to Free Cashflow | 22.5 | ||
| Price to Sales | 2.8 | ||
| EV to EBITDA | 24.43 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.21% | ||
| Return on Equity | -0.68% | ||
| Operating Margin | 3.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | 256.48 | 360.54 | 393.13 | 500.66 | 525.39 | 579 | 640.9 | 13.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +23.45 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Directors
- Jan Egberts CHM (62)
- Daniel Schneider PRE
- Erik Dahl CFO (61)
- Ambaw Bellete CEX
- Gry Stensrud VOP (46)
- Susanne Strauss VPR
- Grete Hogstad VPR (60)
- Anders Neijber VPR
- Inger Ferner Heglund VRD (61)
- Jeremy Bahr OTH
- Espen Njastein OTH
- Einar Antonsen DRC
- Johanna Holldack DRC
- Gwen Mellincoff DRC
- Tove Ringvold DRC
- Grannum Sant DRC
- Tom Pike IND (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 20th, 1995
- Public Since
- May 29th, 2000
- No. of Employees
- 102
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Oslo Stock Exchange- Shares in Issue
- 27,105,698
- Address
- Hoffsveien 4, OSLO, 0275
- Web
- https://photocure.com/
- Phone
- +47 22062210
- Auditors
- KPMG AS
Upcoming Events for PHO
Q1 2025 Photocure ASA Earnings Release
Q2 2025 Photocure ASA Earnings Release
Similar to PHO
Arctic Bioscience AS
Oslo Stock Exchange
Navamedic ASA
Oslo Stock Exchange
Oncoinvent ASA
Oslo Stock Exchange
Vistin Pharma ASA
Oslo Stock Exchange
FAQ
What is the Photocure ASA share price?
As of Today at 22:38 UTC, shares in Photocure ASA are trading at NOK54.20. This share price information is delayed by 15 minutes.
How has the Photocure ASA share price performed this year?
Shares in Photocure ASA last closed at NOK54.20 and the price had moved by +3.86% over the past 365 days. In terms of relative price strength the Photocure ASA share price has outperformed the FTSE Global All Cap Index by +1.26% over the past year.
What are the analyst and broker recommendations for Photocure ASA?
The overall consensus recommendation for Photocure ASA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Photocure ASA dividend yield?
Photocure ASA does not currently pay a dividend.
Does Photocure ASA pay a dividend?
Photocure ASA does not currently pay a dividend.
When does Photocure ASA next pay dividends?
Photocure ASA does not currently pay a dividend.
How do I buy Photocure ASA shares?
To buy shares in Photocure ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Photocure ASA?
As of the previous close price of NOK54.20, shares in Photocure ASA had a market capitalisation of NOK1.47bn.
Where are Photocure ASA shares listed?
Here are the trading details for Photocure ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: PHO
What kind of share is Photocure ASA?
Based on an overall assessment of its quality, value and momentum Photocure ASA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Photocure ASA share price forecast for 2025?
The analyst consensus target price for shares in Photocure ASA is NOK81.50. That is 50.37% above the last closing price of NOK54.20.
Analysts covering Photocure ASA currently have a consensus Earnings Per Share (EPS) forecast of NOK1.42 for the next financial year.
Find out moreWhat is the trend in the Photocure ASA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Photocure ASA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +7.27%.
As of the last closing price of NOK54.20, shares in Photocure ASA were trading +1.38% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Photocure ASA PE Ratio?
The Photocure ASA PE ratio based on its reported earnings over the past 12 months is 35.52. The shares last closed at NOK54.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Photocure ASA?
Photocure ASA's management team is headed by:
- Jan Egberts - CHM
- Daniel Schneider - PRE
- Erik Dahl - CFO
- Ambaw Bellete - CEX
- Gry Stensrud - VOP
- Susanne Strauss - VPR
- Grete Hogstad - VPR
- Anders Neijber - VPR
- Inger Ferner Heglund - VRD
- Jeremy Bahr - OTH
- Espen Njastein - OTH
- Einar Antonsen - DRC
- Johanna Holldack - DRC
- Gwen Mellincoff - DRC
- Tove Ringvold - DRC
- Grannum Sant - DRC
- Tom Pike - IND